Xpovio
Named-patient access overview. Xpovio is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Xpovio (selinexor) is a first-in-class oral selective inhibitor of nuclear export that blocks Exportin 1 (XPO1), developed by Karyopharm Therapeutics. The US Food and Drug Administration first approved Xpovio in July 2019 in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies, with a June 2020 approval for relapsed or refractory diffuse large B-cell lymphoma after at least two lines of systemic therapy, and a December 2020 approval in combination with bortezomib and dexamethasone for previously treated multiple myeloma. Xpovio is dosed orally in regimen-specific weekly schedules with mandatory antiemetic prophylaxis and is dispensed through a specialty pharmacy network with prescriber and patient counselling. Reserve Meds coordinates physician-led cross-border sourcing for international patients.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Xpovio
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Xpovio is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country access guide for Xpovio in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Xpovio
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.